Search company, investor...

Predict your next investment

Alexion, AstraZeneca Rare Disease company logo
Corporation
HEALTHCARE | Biotechnology
alexion.com

Investments

7

Portfolio Exits

2

Partners & Customers

10

Service Providers

3

About Alexion, AstraZeneca Rare Disease

Alexion, AstraZeneca Rare Disease is a biopharmaceutical company. It focuses on serving patients and families affected by rare diseases. Alexion, AstraZeneca Rare Disease was formerly known as Alexion Pharmaceuticals. The company was founded in 1992 and is based in Boston, Massachusetts. In July 2021, Alexion Pharmaceuticals was acquired by AstraZeneca.

Headquarters Location

121 Seaport Boulevard

Boston, Massachusetts, 02210,

United States

+1 475 230 2596

Want to inform investors similar to Alexion, AstraZeneca Rare Disease about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Alexion, AstraZeneca Rare Disease

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Alexion, AstraZeneca Rare Disease in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Alexion, AstraZeneca Rare Disease News

Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market is expected to garner a value of US$ 7.29 Billion by 2033

May 24, 2023

Search jobs 24-May-2023 Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market is expected to garner a value of US$ 7.29 Billion by 2033 The global  Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market  is predicted to exceed an impressive US$ 4.8 Billion in 2023, with a compound annual growth rate (CAGR) of 4.2% from 2023 to 2033. The global Diamond–Blackfan Anemia (DBAAASE) Syndrome Therapeutics market is expected to garner a market value of US$ 7.29 Billion by 2033. Because 90% of infected individuals develop hematologic difficulties during their first year of life, a rise in the incidence of blood disorders catapulted the global diamond-blackfan anemia treatment market over the historical era. Moreover, growing government R&D support, changing lifestyles, and rapidly evolving technology are anticipated to propel market growth in the forecast period. North America dominates the diamond-blackfan anaemia syndrome therapeutics market owing to the presence of major notable stakeholders, high expendable income, increased medical costs, and an established medical sector in this region. According to a report published by Clevel and Clinic, the DBA Registry of North America, a database containing data on people who have this disorder, 25% of people with DBA die before the age of 50 from affiliated medical disorders. DBA UK is a registered charity (1083179) that is governed by a written constitution and run by appointed volunteer groups. They offer support, research, and hope to the DBA community by bringing families together to discuss their experiences, share the most recent health history, and raise funds to assist those with DBA in the United Kingdom. Key Takeaways from the Market Study Global DBAAASE syndrome therapeutics market to expand 1.5x from 2023 to 2033 By treatment, blood transfusions to experience a growth rate of 6.9% Around 2 out of 5 DBAAASE syndrome therapeutics to happen across North America Europe to emerge as an important contributor, expected to surge at a CAGR of 3.7% Treatment through corticosteroids to gain equal traction as blood transfusions “As medical science expands, treatments and therapies for a broad range of blood disorders is gaining major traction. This is boding well for the market on diamond blackfan anemia syndrome, with healthcare providers introducing a plethora of therapies and treatment approaches,” says an FMI analyst. Key Market Players Key players in the Diamond–Blackfan Anemia (DBA)/Aase Syndrome Therapeutics market are Sumitomo Corporation, Johnson & Johnson Private Limited, Novartis AG, Pfizer Inc, Sanofi, Merck KGaA, LEO Pharma A/S, Cipla Inc., GlaxoSmithKline plc, AstraZeneca, Abbott, Bayer AG. In July 2021, AstraZeneca procured Alexion Pharmaceuticals, a global biotech company. With this acquisition, the company will be able to enter the market for rare disease medicines, ushering in a new chapter. Moreover, the acquisition strengthened AstraZeneca’s scientific presence in immunology and would allow the company to continue to pioneer the discovery and development of medicines for patients with rare diseases using Alexion’s new complement-biology system and robust pipeline. In June 2022, Pfizer will collaborate with Sirana Pharma, a biotechnology company. The collaboration would help Pfizer recognize and validate a novel therapeutic concept for unique and severe bone diseases. Key Segments Profiled in the Diamond–Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market Industry Survey By Treatment:

Alexion, AstraZeneca Rare Disease Investments

7 Investments

Alexion, AstraZeneca Rare Disease has made 7 investments. Their latest investment was in Caelum Biosciences as part of their Corporate Minority on January 1, 2019.

CBI Logo

Alexion, AstraZeneca Rare Disease Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/31/2019

Corporate Minority

Caelum Biosciences

$30M

Yes

1

6/11/2018

Partnership

Subscribe to see more

Subscribe to see more

10

8/24/2016

Series F

Subscribe to see more

$99M

Subscribe to see more

10

3/3/2015

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2014

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/31/2019

6/11/2018

8/24/2016

3/3/2015

12/19/2014

Round

Corporate Minority

Partnership

Series F

Partnership

Series E

Company

Caelum Biosciences

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$30M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Alexion, AstraZeneca Rare Disease Portfolio Exits

2 Portfolio Exits

Alexion, AstraZeneca Rare Disease has 2 portfolio exits. Their latest portfolio exit was Moderna Therapeutics on December 07, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/7/2018

IPO

$99M

Public

5

4/30/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/7/2018

4/30/2015

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

5

10

Alexion, AstraZeneca Rare Disease Acquisitions

9 Acquisitions

Alexion, AstraZeneca Rare Disease acquired 9 companies. Their latest acquisition was LogicBio Therapeutics on November 16, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/16/2022

Series B

$99M

$49M

Take Private

9

9/29/2021

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/5/2020

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

10

10/16/2019

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

9/26/2018

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

11/16/2022

9/29/2021

5/5/2020

10/16/2019

9/26/2018

Investment Stage

Series B

Other

Series D

Other Venture Capital

Series B

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$49M

$99M

$99M

$99M

$99M

Note

Take Private

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

9

10

10

10

10

Alexion, AstraZeneca Rare Disease Partners & Customers

10 Partners and customers

Alexion, AstraZeneca Rare Disease has 10 strategic partners and customers. Alexion, AstraZeneca Rare Disease recently partnered with JCR Pharmaceuticals on April 4, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

4/3/2023

Licensor

Japan

JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease

JCR Pharmaceuticals Co. , Ltd. -LRB- TSE 4552 ; Chairman and President : Shin Ashida ; `` JCR Pharmaceuticals Co. , Ltd. '' -RRB- today announced that JCR Pharmaceuticals Co. , Ltd. has signed a Research Collaboration , Option and License Agreement with Alexion , AstraZeneca Rare Disease -LRB- `` Alexion '' -RRB- to develop an undisclosed initial therapeutic molecule that applies JCR Pharmaceuticals Co. , Ltd. 's proprietary J-Brain Cargo ® Technology , blood-brain barrier -LRB- `` BBB '' -RRB- penetration technology , for the treatment of a neurodegenerative disease .

2

3/10/2022

Partner

Denmark

Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.

Under the terms of the agreement , Alexion Pharmaceuticals and Zealand Pharma entered into an exclusive collaboration for the discovery and development of subcutaneously delivered peptide therapies directed to up to four complement pathway targets .

3

1/3/2022

Licensor

Switzerland

Neurimmune Enters Into A Collaboration And License Agreement With AstraZeneca To Develop And Commercialize NI006

ZURICH , Jan. 7 , 2022 / PRNewswire / -- Neurimmune today announced that it has entered into an exclusive global collaboration and license agreement with Alexion , AstraZeneca 's Rare Disease group , to develop NI006 , an investigational human monoclonal ... Author :

5

11/11/2021

Partner

Denmark

Subscribe to see more

Subscribe to see more

10

9/20/2021

Vendor

United States

Subscribe to see more

Subscribe to see more

10

Date

4/3/2023

3/10/2022

1/3/2022

11/11/2021

9/20/2021

Type

Licensor

Partner

Licensor

Partner

Vendor

Business Partner

Country

Japan

Denmark

Switzerland

Denmark

United States

News Snippet

JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease

JCR Pharmaceuticals Co. , Ltd. -LRB- TSE 4552 ; Chairman and President : Shin Ashida ; `` JCR Pharmaceuticals Co. , Ltd. '' -RRB- today announced that JCR Pharmaceuticals Co. , Ltd. has signed a Research Collaboration , Option and License Agreement with Alexion , AstraZeneca Rare Disease -LRB- `` Alexion '' -RRB- to develop an undisclosed initial therapeutic molecule that applies JCR Pharmaceuticals Co. , Ltd. 's proprietary J-Brain Cargo ® Technology , blood-brain barrier -LRB- `` BBB '' -RRB- penetration technology , for the treatment of a neurodegenerative disease .

Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.

Under the terms of the agreement , Alexion Pharmaceuticals and Zealand Pharma entered into an exclusive collaboration for the discovery and development of subcutaneously delivered peptide therapies directed to up to four complement pathway targets .

Neurimmune Enters Into A Collaboration And License Agreement With AstraZeneca To Develop And Commercialize NI006

ZURICH , Jan. 7 , 2022 / PRNewswire / -- Neurimmune today announced that it has entered into an exclusive global collaboration and license agreement with Alexion , AstraZeneca 's Rare Disease group , to develop NI006 , an investigational human monoclonal ... Author :

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

3

5

10

10

Alexion, AstraZeneca Rare Disease Service Providers

4 Service Providers

Alexion, AstraZeneca Rare Disease has 4 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Alexion, AstraZeneca Rare Disease Team

29 Team Members

Alexion, AstraZeneca Rare Disease has 29 team members, including , .

Name

Work History

Title

Status

Scott Rollins

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Scott Rollins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Alexion, AstraZeneca Rare Disease to Competitors

R
Retrotope

Retrotope develops a drug platform to preserve and restore mitochondrial health in degenerative diseases. The mechanism of Retrotope's platform prevents cellular damage and recovers cellular function damaged by lipid peroxidation due to oxidative stress.

Annexon Biosciences Logo
Annexon Biosciences

Annexon Biosciences (NASDAQ: ANNX) operates a clinical-stage biopharmaceutical company. The company stimulates an immune-mediated solution that causes cell loss and tissue damage in autoimmune, neurodegenerative, and ophthalmic disorders. The company was founded in 2011 and is based in Brisbane, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.